Premature senescence in primary muscle cultures of myotonic dystrophy type 2 is not associated with p16 induction

European Journal of Histochemistry

Volumn 58, Issue 4, 2014, Pages 275-286

  Renna, L V ^a   Cardani, R ^b   Botta, A ^c   Rossi, G ^c   Fossati, B ^d   Costa, E ^b   Meola, Giovanni ^b,d  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Aging; Myoblasts; Myotonic dystrophy; P16; Telomeres

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MUSCLE PROTEIN;

BIOSYNTHESIS; CELL AGING; CELL CULTURE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MYOTONIC DYSTROPHY; PATHOLOGY; SKELETAL MUSCLE CELL;

CELL AGING; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MYOTONIC DYSTROPHY;

EID: 84908292875     PISSN: 1121760X     EISSN: 20388306     Source Type: Journal    
DOI: 10.4081/ejh.2014.2444     Document Type: Article

References (55)

1. Harper PS. Myotonic dystrophy, 3th ed. Sanders, London, UK, 2001.
2. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcipt encoding a protein kinase family member. Cell 1992;68:799-808.
3. Fu YH, Pizzuti A, Fenwick RG Jr, King J, Rajnarayan S, Dunne PW, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992;255:1256-8.
4. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992;255:1253-5.
5. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293:864-7.
6. Ranum LP, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet 2004;74:793-804.
7. Miller JW, Urbinati CR, Teng-umnuay P, Stenberg MG, Byrne BJ, et al. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J 2000;19:4439- 48.
8. Mankodi A, Urbinati CR, Yuan QP, Moxley RT, Sansone V, Krym M, et al. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet 2001;10:2165-70.
9. Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, Timchenko LT. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem 2001;276:7820-6.
10. Perdoni F, Malatesta M, Cardani R, Giagnacovo M, Mancinelli E, Meola G, et al. RNA/MBNL1-containing foci in myoblast nuclei from patients affected by myotonic dystrophy type 2: an immunocytochemical study. Eur J Histochem 2009; 53:151-58.
11. Osborne RJ, Thornton CA. RNA-dominant diseases. Hum Mol Genet 2006;15:R162-9.
12. Meola G, Cardani R. RNA binding proteins in myotonic dystrophies, pp. 153-66. In: RB Denman (ed.) RNA binding proteins in development and disease. Research Signpost, Kerala, 2009.
13. Vihola A, Bassez G, Meola G, Zhang S, Haapasalo H, Paetau A, et al. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology 2003;60:1854-7.
14. Bassez G, Chapoy E, Bastuji-Garin S, Radvanyi-Hoffman H, Authier FJ, Pellisser JF, et al. Type 2 myotonic dystrophy can be predicted by the combination of type 2 muscle fibre central nucleation and scattered atrophy. J Neuropathol Exp Neurol 2008;67:319-25.
15. Pisani V, Panico MB, Terracciano C, Bonifazi E, Meola G, Novelli G, et al. Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2. Muscle Nerve 2008;38:1405-11.
16. Shavlakadze T, Grounds M. Of bears, frogs, meat, mice and men: complexity of factors affecting skeletal muscle mass and fat. Bioessays 2006;28:994-1009.
17. Mouly V, Aamiri A, Bigot A, Cooper RN, Di Donna S, Furling D, et al. The mitotic clock in skeletal muscle regeneration, disease and cell mediated gene therapy. Acta Physiol Scand 2005;184:3-15.
18. Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J 2013;280:4294-314.
19. Moss FP, Leblond CP. Satellite cells as the source of nuclei in muscles of growing rats. Anat Rec 1971;170:421-35.
20. Malatesta M. Skeletal muscle features in myotonic dystrophy and sarcopenia: do similar nuclear mechanisms lead to skeletal muscle wasting? Eur J Histochem 2012;56:e36 .
21. Relaix F, Zammit PS. Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. Development 2012;139:2845-56.
22. Bischoff R, Heintz C. Enhancement of skeletal muscle rigeneration. Dev Dyn 1994;201:41-54.
23. Cooper RN, Tajbakhsh S, Mouly V, Cossu G, Buckingham M, et al. In vivo satellite cell activation via Myf5 and MyoD in rigenerating mouse skeletal muscle. J Cell Sci 1999; 112:2895-901.
24. Renault V, Thornell LE, Butler-Browne G, Mouly V.Human skeletal muscle satellite cells: aging, oxidative stress and the mitotic clock. Exp Gerontol 2002;37:1229-36.
25. Renault V, Thornell LE, Eriksson PO, Butler-Browne G, Mouly V. Regenerative potential of human skeletal muscle during aging. Aging Cell 2002;1:132-9.
26. Wright WE, Shay JW. Historical claims and current interpretations of replicative aging. Nat Biotechnol 2002;20:682-8.
27. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349-52.
28. Zhu CH, Mouly V, Cooper RN, Mamchaoui K, Bigot A, Shay JW, et al. Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell 2007;6:515-23.
29. Bigot A, Jacquemin V, Debacq-Chainiaux F, Butler-Browne G, Toussaint O, Furling D, et al. Replicative aging down-regulates the myogenic regulatory factors in human myoblasts. Biol. Cell 2008;100:189-99.
30. Decary S, Hamida CB, Mouly V, Barbet JP, Hentati F, Butler-Browne GS. Shorter telomeres in dystrophic muscle consistent with extensive regeneration in young children. Neuromuscul Disord 2000;10:113-20.
31. Périé S, Mamchaoui K, Mouly V, Blot S, Bouazza B, Thornell LE, et al. Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: therapeutic perspectives of autologous myoblast transplantation. Neuromuscul Disord 2006;16:770-81.
32. Morosetti R, Broccolini A, Sancricca C, Gliubizzi C, Gidaro T, Tonali PA, et al. Increased aging in primary muscle cultures of sporadic inclusion-body myositis. Neurobiol Aging 2010;31:1205-14.
33. Furling D, Coiffier L, Mouly V, Barbet JP, Lacau St Guily J, Taneja K, et al. Defective satellite cells in congenital myotonic dystrophy. Hum Mol Genet 2001;10:2079-87.
34. Thornell LE, Lindstöm M, Renault V, Klein A, Mouly V, Ansved T, et al. Satellite cell dysfunction contributes to the progressive muscle atrophy in myotonic dystrophy type 1. Neuropathol Appl Neurobiol 2009;35: 603-13.
35. Bigot A, Klein AF, Gasnier E, Jacquemin V, Ravassard P, Butler-Brown G, et al. Large CTG repeats trigger p16-dependent premature senescence in myotonic dystrophy type 1 muscle precursor cells. Am J Pathol 2009;174:1435-42.
36. Malatesta M, Giagnacovo M, Renna LV, Cardani R, Meola G, Pellicciari C. Cultured myoblasts from patients affected by myotonic dystrophy type 2 exhibit senescence- related features: ultrastructural evidence. Eur J Histochem 2011;55:e26.
37. Moxley 3rd RT, Meola G, Udd B, Ricker K. Report of the 84th ENMC workshop: PROMM (proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13-15th October 2000, Loosdrecht: The Netherlands. Neuromuscul Disord 2002;12:306-17.
38. Cardani R, Mancinelli E, Sansone V, Rotondo G, Meola G. Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy. Eur J Histochem 2004;48:437-42.
39. Botta A, Bonifazi E, Vallo L, Gennarelli M, Garrè C, Salesi L, et al. Italian Guidelines for molecular analysis in myotonic dystrophy. Acta Myol 2006;25:23-33.
40. Bonifazi E, Vallo L, Giardina E, Botta A, Novelli G. A long PCR-based molecular protocol for detecting normal and expanded ZNF9 alleles in myotonic dystrophy type 2. Diagn Mol Pathol 2004;13:164-6.
41. Valaperta R, Sansone V, Lombardi F, Verdelli C, Colombo A, Valisi M, et al. Identification and characterization of DM1 patients by a new diagnostic certified assay: neuromuscular and cardiac assessments. Biomed Res Int 2013;2013:958510.
42. Dubowitz V. Muscle biopsy, pp. 19-40. In: V Dubowitz (ed.) A practical approach. Bailliere Tindall, London, 1985.
43. Cardani R, Baldassa S, Botta A, Rinaldi F, Novelli G, Mancinelli E, et al. Ribonuclear inclusions and MBNL1 nuclear sequestration do not affect myoblast differentiation but alter gene splicing in myotonic dystrophy type 2. Neuromuscul Disor 2009;19:335-43.
44. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995;92:9363-7.
45. Kimura M, Stone RC, Hunt SC, Skurnick J, Lu X, Cao X, et al. Measurement of telomere length by the Southern blot analysis of terminal restriction fragment lengths. Nat Protoc 2010;5:1596-607.
46. Malatesta M, Giagnacovo M, Cardani R, Meola G, Pellicciari C. RNA processing is altered in skeletal muscle nuclei of patients affected by myotonic dystrophy. Histochem Cell Biol 2011;135:419-25.
47. Malatesta M, Perdoni F, Muller S, Zancanaro C, Pellicciari C. Nuclei of aged myofibres undergo structural and functional changes suggesting impairment in RNA processing. Eur J Histochem 2009; 53:97-106.
48. Malatesta M, Giagnacovo M, Costanzo M, Cisterna B, Cardani R, Meola G. Muscleblind-like1 undergoes ectopic relocation in the nuclei of skeletal muscles in myotonic dystrophy and sarcopenia. Eur J Histochem 2013;57:e15.
49. Machida S, Narusawa M. The roles of satellite cells and hematopoietic stem cells in impaired regeneration of skeletal muscle in old rats. Ann N Y Acad Sci 2006;1067: 349-53.
50. Verdijk LB, Koopman R, Schaart G, Meijer K, Savelberg HH, van Loon LJ. Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. Am J Physiol Endocrinol Metab 2007;292:E151- 7.
51. Pelletier R, Hamel F, Beaulieu D, Patry L, Haineault C, Tarnopolsky M, et al. Absence of a differentiation defect in muscle satellite cells from DM2 patients. Neurobiol Dis 2009;36:181-90.
52. Loro E, Rinaldi F, Malena A, Masiero E, Novelli G, Angelini C, et al. Normal myogenesis and increased apoptosis in myotonic dystrophy type-1 muscle cells. Cell Death Differ 2010;17:1315-24.
53. Decary S, Mouly V, Hamida CB, Sautet A, Barbet JP, Butler-Browne GS. Replicative potential and telomere length in human skeletal muscle: implications for satellite cell-mediated gene therapy. Hum Gene Ther 1997;8:1429-38.
54. Lorenzon P, Bandi E, de Guarrini F, Pietrangelo T, Schäfer R, Zweyer M, et al. Ageing affects the differentiation potential of human myoblasts. Exp Gerontol 2004; 39:1545-54.
55. Mathieu J, Boivin H, Meunier D, Gaudreault M, Bégin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001;56:336-40.